Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AnaptysBio Inc ANAB

Healthcare Biotechnology
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032... see more

Recent & Breaking News (NDAQ:ANAB)

AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

GlobeNewswire August 8, 2022

AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

GlobeNewswire August 5, 2022

AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

GlobeNewswire June 2, 2022

AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update

GlobeNewswire May 4, 2022

AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates

GlobeNewswire April 27, 2022

AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer

GlobeNewswire March 21, 2022

AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne

GlobeNewswire March 14, 2022

AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update

GlobeNewswire March 7, 2022

AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2022

AnaptysBio Announces Appointment of Daniel Faga to Board of Directors

GlobeNewswire November 29, 2021

AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference

GlobeNewswire November 15, 2021

AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data

GlobeNewswire November 15, 2021

AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates

GlobeNewswire November 4, 2021

AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard

GlobeNewswire October 25, 2021

AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis

GlobeNewswire October 2, 2021

AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 9, 2021

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

GlobeNewswire August 17, 2021

AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates

GlobeNewswire August 9, 2021

AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

GlobeNewswire May 27, 2021

AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

GlobeNewswire May 4, 2021